PRT-2527 is under clinical development by Prelude Therapeutics and currently in Phase I for Solid Tumor. According to GlobalData, Phase I drugs for Solid Tumor have a 54% phase transition success rate (PTSR) indication benchmark for progressing into Phase II. GlobalData’s report assesses how PRT-2527’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
PRT-2527 is under development for the treatment of aggressive B-cell lymphoma subtypes, mantle cell lymphoma (MCL), and chronic lymphocytic lymphoma (CLL)/small lymphocytic lymphoma (SLL), including Richter's syndrome, acute myelocytic leukemia, non-small cell lung cancer and solid tumors including sarcomas, human epidermal growth factor receptor 2 negative breast cancer (HER2- breast cancer), hormone refractory (castration resistant, androgen-independent) prostate cancer, breast cancer and other cancers with genomic alterations that lead to MYC dependence. It is administered through intravenous route. The drug candidate acts by targeting cyclin dependent kinase 9 (CDK9).
It was also under development for the treatment of triple-negative breast cancer (TNBC), synovial sarcoma.
Prelude Therapeutics overview
Prelude Therapeutics (Prelude) is a biopharmaceutical company focused on discovering as well as developing small molecule therapies for the treatment of cancers with high unmet need. The company leverages its core competencies in medicinal chemistry and cancer biology coupled with agnostic approach target class and technology platform for drug discovery and creating new chemical entities. Pipeline candidates of the company include PRT543 for solid tumors and myeloid malignancies; PRT811 for GBM and CNS metastatic cancers; PRT1419 and PRT2527 for hematological malignancies; PRT-SCA2 for multiple genomically cancer and PRT-K4 for solid tumors. Prelude is headquartered in Wilmington, Delaware, the United States.
For a complete picture of PRT-2527’s drug-specific PTSR and LoA scores, buy the report here.